Wells Fargo Rates Fertility-Benefits Provider Progyny a Strong Buy
Wells Fargo analysts have rated fertility-benefits provider Progyny as a 'strong buy,' citing its position as the category leader and significant untapped market potential. Currently serving around 7 million patients across more than 600 companies, Wells Fargo estimates that Progyny could reach up to 156 million people in the future. The company reported nearly $1.3 billion in revenue for the past fiscal year, a 10% increase driven by expansion beyond basic fertility services. The U.S. fertility rate has dropped significantly over two decades but is expected to rebound as more women delay childbirth and seek medical assistance during their later reproductive years. Progyny competes with Carrot, another provider offering employer-based fertility benefits through different models—Progyny offers bundled treatments while Carrot provides fixed lifetime funds. A proposed policy by former President Trump could further expand the market for these services by allowing employers to offer standalone fertility and IVF insurance. This development may encourage more companies to partner with third-party providers like Progyny, potentially increasing demand.
Topics: fertility benefits Progyny stock ratings Wells Fargo